BioPharmSignal logoBioPharmSignal

Biotech News

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

Humacyte (HUMA)HumacyteEarnings

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and

Related news

HUMAHumacyte2026-05-08 12:00 EST

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

HUMAHumacyte2026-08-12 11:00 EST

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

HUMAHumacyte2026-08-24 12:00 EST

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

HUMAHumacyte2026-08-19 12:00 EST

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

HUMAHumacyte2026-08-18 12:00 EST

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

HUMAHumacyte2026-08-12 11:00 EST

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

HUMAHumacyte2026-08-07 12:00 EST

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026

Stock data

Close
0.64 USD
Market cap
308.61M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States